drugset / Trial / NCT07029581
Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Multicenter, randomized, 6-week, double-blind, placebo-controlled, parallel-group, Phase 2 study in subjects with LBDP.
Timeline
- Start
- 2025-08-06
- Primary completion
- 2028-02
- Completion
- 2028-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ACP-204 | Unknown | 30 mg | Oral |
| Subject | ACP-204 | Unknown | 60 mg | Oral |